Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis von Lampertico, P., Aleman, S., Blank, A., Bogomolov, P., Chulanov, V., Mamonova, N., Morozov, V., Sagalova, O., Stepanova, T., Suri, V., Manuilov, D., Ye, L., Flaherty, J.F., Osinusi, A., Cornberg, M., Brunetto, M., Wedemeyer, H.

Volltext

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data von Asselah, T., Lampertico, P., Aleman, S., Bourliere, M., Streinu-Cercel, A., Bogomolov, P., Morozov, V., Stepanova, T., Lazar, S., Suri, V., Manuilov, D., Mercier, R.C., Tseng, S., Ye, L., Flaherty, J.F., Osinusi, A., Brunetto, M., Wedemeyer, H.

Volltext

Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks von Buti, M., Wedemeyer, H., Aleman, S., Chulanov, V., Morozov, V., Sagalova, O., Stepanova, T., Gish, R. G, Lloyd, A., Kaushik, A. M, Suri, V., Manuilov, D., Osinusi, A. O, Flaherty, J., Pandey, S., Singh, B., Lampertico, P.

Volltext

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D von Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro

Volltext

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection von Sandmann, Lisa, Degasperi, Elisabetta, Port, Kerstin, Aleman, Soo, Wallin, Jeffrey J, Manuilov, Dmitry, Da, Ben L, Cornberg, Markus, Lampertico, Pietro, Maasoumy, Benjamin, Wedemeyer, Heiner, Deterding, Katja

Volltext

No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta von Hollnberger, Julius, Liu, Yang, Xu, Simin, Chang, Silvia, Martin, Ross, Manhas, Savrina, Aeschbacher, Thomas, Han, Bin, Yazdi, Tahmineh, May, Lindsey, Han, Dong, Shornikov, Alex, Flaherty, John, Manuilov, Dmitry, Suri, Vithika, Asselah, Tarik, Lampertico, Pietro, Wedemeyer, Heiner, Aleman, Soo, Richards, Christopher, Mateo, Roberto, Maiorova, Evguenia, Cihlar, Tomas, Mo, Hongmei, Urban, Stephan

Volltext

Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in... von Lampertico, Pietro, Wedemeyer, Heiner, Brunetto, Maurizia, Bogomolov, Pavel, Stepanova, Tatyana, Ciesek, Sandra, Berger, Annemarie, Manuilov, Dmitry, An, Qi, Lau, Audrey, Da, Ben, Flaherty, John F., Mercier, Renee-Claude, Zeuzem, Stefan, Cornberg, Markus, Buti, Maria, Aleman, Soo

Volltext

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial von Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Ciesek, Sandra, Manuilov, Dmitry, Mercier, Renee-Claude, Da, Ben L., Chee, Grace M., Li, Mingyang, Flaherty, John F., Lau, Audrey H., Osinusi, Anu, Schulze zur Wiesch, Julian, Cornberg, Markus, Zeuzem, Stefan, Lampertico, Pietro

Volltext

Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study von Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Viacheslav, Morozov, Sagalova, Olga, Stepanova, Tatyana, Manuilov, Dmitry, Mercier, Renee-Claude, An, Qi, Flaherty, John F., Osinusi, Anu, Lau, Audrey, zur Wiesch, Julian Schulze, Cornberg, Markus, Zeuzem, Stefan, Lampertico, Pietro

Volltext

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic... von Lampertico, Pietro, Aleman, Soo, Asselah, Tarik, Bourliere, Marc, Streinu-Cercel, Adrian, Bogomolov, Pavel, Viacheslav, Morozov, Stepanova, Tatyana, Lazar, Stefan, Suri, Vithika, Manuilov, Dmitry, Ye, Lei, Flaherty, John F., Osinusi, Anu, Brunetto, Maurizia, Wedemeyer, Heiner

Volltext

Structure of Information Model of Steel Tanks von Mokrozub, V. G., Manuilov, K. D., Gorshkov, V. V., Gorshkova, T. S.

Volltext

Efficacy of bulevirtide as monotherapy for chronic hepatitis delta: Week 48 results from an integrated analysis von Freismuth, A, Lampertico, P, Aleman, S, Blank, A, Bogomolov, P, Chulanov, V, Mamonova, N, Morozov, V, Sagalova, O, Stepanova, T, Suri, V, Manuilov, D, Ye, L, Flaherty, JF, Osinusi, AO, Cornberg, M, Brunetto, M, Wedemeyer, H

Volltext

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: An integrated safety analysis of 48-week data von Freismuth, A, Asselah, T, Lampertico, P, Aleman, S, Bourliere, M, Streinu-Cercel, A, Bogomolov, P, Morozov, V, Stepanova, T, Lazar, S, Suri, V, Manuilov, D, Mercier, RC, Tseng, S, Ye, L, Flaherty, JF, Osinusi, AO, Brunetto, M, Wedemeyer, H

Volltext

RELATIONSHIP BETWEEN ALT NORMALIZATION RATES AND DIFFERENT VIROLOGIC RESPONSE CRITERIA IN CHRONIC HDV PATIENTS TREATED WITH BULEVIRTIDE MONOTHERAPY von Lampertico, P, Aleman, S, Bogomolov, P, Stepanova, T, Cornberg, M, Ciesek, S, Berger, A, Manuilov, D, An, Q, Lau, AH, Da, BL, Flaherty, JF, Mercier, RC, Liu, Y, Brunetto, MR, Zeuzem, S, Wedemeyer, H

Volltext

BULEVIRTIDE IMPROVES HEALTH RELATED QUALITY LIFE MEASURED BY EQ-5D VAS IN PATIENTS WITH CHRONIC HEPATITIS DELTA: AN EXPLORATORY ANALYSIS OF A PHASE 3 TRIAL AT 48 WEEKS von Buti, M, Wedemeyer, H, Aleman, S, Chulanov, V, Morozov, V, Sagalova, O, Stepanova, T, Gish, RG, Lloyd, A, Kaushik, AM, Suri, V, Manuilov, D, Osinusi, AO, Flaherty, JF, Pandey, S, Singh, B, Lampertico, P

Volltext

BULEVIRTIDE MONOTHERAPY IS SAFE AND WELL TOLERATED IN PATIENTS WITH CHRONIC HEPATITIS D (CHD): AN INTEGRATED SAFETY ANALYSIS OF 48-WEEK DATA von Asselah, T, Lampertico, P, Aleman, S, Bourliere, M, Streinu-Cercel, A, Bogomolov, P, Morozov, V, Stepanova, T, Lazar, S, Suri, V, Manuilov, D, Mercier, RC, Tseng, S, Ye, L, Flaherty, JF, Osinusi, AO, Brunetto, M, Wedemeyer, H

Volltext

Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study von Freismuth, A, Wedemeyer, H, Aleman, S, Brunetto, M, Black, A, Andreone, P, Bogomolov, P, Chulanov, V, Mamonova, N, Geyvandova, N, Morozov, V, Sagalova, O, Stepanova, T, Manuilov, D, Suri, V, An, Q, Flaherty, JF, Osinusi, A, Zur Wiesch, JS, Cornberg, M, Zeuzem, S, Lampertico, P

Volltext

Synthesis of multilobe array-antenna patterns with controlled levels, phases, and polarization of the pattern maxima von Bashly, P. N., Manuilov, B. D., Kuznetsov, Yu. A.

Volltext

DEVELOPMENT OF ANTIDRUG ANTIBODIES ON BULEVIRTIDE MONOTHERAPY IN CHD DOES NOT IMPACT BULEVIRTIDE EFFICACY, SAFETY OR PHARMACOKINETICS von Lampertico, P, Aleman, S, Bogomolov, P, Morozov, V, Mamonova, N, Manuilov, D, Ye, L, Da, B, Mercier, RC, Lau, AH, Chee, G, Mallalieu, N, Kumar, P, Stepanova, T, Chulanov, V, Zeuzem, S, Wedemeyer, H, Bourliere, M, Zoulim, F, Asselah, T, Brunetto, MR, Cornberg, M, Blank, A

Volltext

Synthesis of the pattern nulls of a planar-waveguide array with dielectric inserts von Manuilov, B D, Bashly, P N, Shablovsky, V M

Volltext